Board summary
Key figures
51,712
Registered population
64.6% aged 18–64
13.1%
Aged 65+
ICB 21.9% · England 17.9%
26.4%
Ethnic minority (non-White)
15.4% Asian · England 9.6%
0.4%
In IMD quintile 1
ICB 9.2% · England 21.0%
~134
Core20 residents (est.)
Resident basis; registered basis ~129 · see page 3
6,811
Hypertension register
+0.64% in 3 yrs · England +5.60%
499
SMI register
39.1% of Crawley's
871
COPD register
Reviews +25.06% in 3 yrs
Forecast to 2030
7,336
Hypertension patients, 2030
+525 on today
77.9%
QRISK ≥20% on statins, 2030
+2.83pp over 3 yrs
2.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Fifteen of twenty-five measures trail England's trend.
Over 2023 to 2025, hypertension prevalence rose +0.6% (England +5.6%), stroke fell 2.4% (+2.3%) and dementia fell 19.5% (+6.0%), which may reflect unverified coding.
Age-five booster and MMR2 miss 95.0% target.
At age 5 in Q1 2025/26, 4-in-1 booster is 12.9 pp below the 95.0% target and MMR2 (86.1%) is 8.9 pp below, suggesting recall.
Cardiovascular and SMI care exceed England averages.
QRISK ≥ 20% lipid therapy reaches 71.9% (England 63.6%), SMI blood pressure checks reach 89.3% (83.4%) and under-80s hypertension control reaches 70.5% (67.8%).
Population, age and ethnicity
A younger list with 13.1% aged 65+ and 15.4% Asian residents may influence demand
Across 51,712 registered patients, the PCN has a younger age profile: 13.1% are aged 65+ (Crawley 13.7%, NHS Sussex Integrated Care Board 21.9%, England 17.9%) and 22.4% are aged 0-17 (Crawley 22.1%, NHS Sussex Integrated Care Board 17.7%, England 19.6%). Census usual residents indicate a 26.4% ethnic minority share, including 15.4% Asian / Asian British residents (Crawley 15.4%, NHS Sussex Integrated Care Board 3.7%, England 9.6%), recorded at Leacroft Medical Practice (18.9%) and Southgate Medical Group (15.6%). Age figures use registered patients, whereas ethnicity reflects resident catchment populations.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Crawley local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Crawley LA) | 2,574 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 87.5% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.3% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Crawley LA) | 1,205 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Crawley LA) | 12.6 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 0.4% overall and concentrated within Southgate Medical Group
The PCN Core20 cohort is 0.4%, below Crawley (1.3%), NHS Sussex Integrated Care Board (9.2%) and England (21.0%), while average IMD decile is 4.8 (England 5.5). Weighted practice share is 0.2% against the PCN's 0.4%, and resident estimates indicate 134 people. Southgate Medical Group records a 1.1% Core20 share (129 estimated patients), whereas Leacroft Medical Practice, Bridge Medical Centre and Langley Corner Surgery each record 0.0%. Recorded Core20 patients concentrate at Southgate Medical Group, indicating proactive outreach can focus on that practice.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
499
SMI register
0.98% recorded prevalence
497
Learning disability register
0.97% recorded prevalence
23
Care homes, 395 beds
In the PCN catchment
8.7%
Provide unpaid care
Crawley, Census 2021
The PCN records 497 learning disability patients (1.0% prevalence vs Crawley 0.8%, NHS Sussex Integrated Care Board 0.6%, England 0.6%) and 499 severe mental illness patients (1.0% vs Crawley 0.9%, NHS Sussex Integrated Care Board 1.1%, England 1.0%), alongside 23 catchment care homes with 395 beds. Crude register prevalence does not establish unmet need, and care home beds do not establish resident patient numbers.
Severe mental illness: physical health checks
Recorded SMI blood pressure checks reached 89.3% and BMI checks 89.8%, exceeding England (83.4% and 82.1%). Smoking cessation offers fell 3.8 pp over 2023 to 2025 (England +0.1 pp) to 92.3% (England 94.2%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,811
Hypertension register
+0.64%
Register growth, 3 yrs
Crawley +6.33% · England +5.60%
−0.92pp
BP control, under 80
≤140/90 · +3.49pp aged 80+
+525
More patients by 2030
Forecast 7,336 (13.49%)
Hypertension case-finding and control
Recorded hypertension prevalence is 13.3% (6,811 patients), below Crawley (13.8%), England (15.2%) and NHS Sussex Integrated Care Board (16.3%). Register growth over 2023 to 2025 rose +0.6% (+0.1 pp), trailing Crawley (+6.3%) and England (+5.6%), which may reflect a younger list (13.1% aged 65+ vs England 17.9%). An unadjusted benchmark scenario implies +348 to +1,065 patients. Recent blood pressure monitoring is 93.4% (England 90.0%). Under-80 blood pressure control (<= 140/90 mmHg) is 70.5% (England 67.8%), but slipped 0.9 pp over 2023 to 2025 while England rose +2.1 pp. Hypertension control leads national averages, but slower register growth and slipping younger-cohort control highlight an opportunity to strengthen opportunistic detection and systematic recall.
Lipids and statins
For QRISK >= 20%, lipid therapy is 71.9%, exceeding England (63.6%) and Crawley (65.9%). Primary statin coverage in diabetes is 74.1% (England 73.2%), but fell 1.5 pp over 2023 to 2025 (England +1.5 pp). Above-average lipid reach positions the PCN well, while slipping diabetic statin coverage warrants targeted recall.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 87,982 | £2.10 | £2.42 | £1.86 | £184,762 |
| Cardiovascular (all), 2025 | 105,302 | £2.62 | £3.32 | £3.33 | £275,891 |
In 2026, the PCN prescribed 87,982 lipid-modifying items at £2.10 per item (England £1.86, Crawley £2.34, NHS Sussex Integrated Care Board £2.42). Spend was £184,762, which is £21,116 more than at England's unit cost and £28,154 less than at the ICB rate. Unit-cost differences reflect local formulary choices and case-mix rather than an efficiency saving target.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+9.53%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.55%
Asthma prevalence, PCN 3-yr % change
COPD review coverage reached 74.6% (England 76.4%), up +25.1% over 2023 to 2025 (England +2.8%), while COPD prevalence stands at 1.7% (England 1.9%). Asthma reviews reached 67.4% (England 65.7%), rising +9.5% over 2023 to 2025 (England +4.4%), although asthma register prevalence fell 1.6% (England +0.5%) to 6.9%. Across the 3,272-patient asthma register, a scale estimate of 1,067 patients lacked a recorded annual review, with Bridge Medical Centre recording 51.0%.
Cancer register and children's immunisation
Cancer register prevalence is 2.8% (Crawley 3.2%, England 3.8%), rising +2.3% over 2023 to 2025 (England +9.0%). In childhood immunisations (Q1 2025/26), 24-month 6-in-1 coverage reached 96.0%, exceeding the 95.0% target by 1 pp. However, age-five coverage fell below the 95.0% target by 8.9 pp for MMR2 (86.1%) and by 12.9 pp for the 4-in-1 booster (82.1%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022, 58.5% of staged cancers across NHS Sussex ICB were diagnosed at stage 1 or 2 (England 55.3%), below the 75.0% national ambition. Known-stage completeness was 64.3% (8,209 of 12,766 registered cancers; England 67.0%). Across the ICB, reaching 75.0% early diagnosis would require about 1,360 additional early-stage cases annually. Staging data reflects ICB registry figures, not PCN performance. At PCN level, cancer register growth of +2.3% over 2023 to 2025 (England +9.0%) may reflect a younger list but indicates a need to verify whether primary care case-finding and coding are keeping pace.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Surrey and Sussex Healthcare NHS Trust achieved 77.7% on the 28-day faster diagnosis standard (standard 75.0%), but reached 70.0% on the 62-day treatment standard (standard 85.0%). Comparatively, 62-day delivery was 86.8% at Epsom and St Helier University Hospitals NHS Trust, 71.5% across NHS Surrey and Sussex Integrated Care Board, 71.2% in England, and 65.2% at University Hospitals Sussex NHS Foundation Trust. Diagnostic 6-week waits at the trust reached 28.5% (England 23.1%), with cystoscopy at 43.1% and Magnetic Resonance Imaging at 27.5%. These figures reflect provider activity, not PCN performance.
| Pathways within standard (%) | Surrey and Sussex Healthcare | Sussex | Epsom and St Helier | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.74 | 74.01 | 89.70 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.20 | 76.79 | 99.16 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 69.97 | 65.20 | 86.82 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Surrey and Sussex Healthcare | Sussex | Epsom and St Helier | England |
|---|---|---|---|---|
| MRI | 27.53 | 5.62 | 0.31 | 21.40 |
| CT | 18.49 | 8.57 | 1.06 | 9.92 |
| Echocardiography | 43.78 | 0.39 | 25.49 | 28.48 |
| Colonoscopy | 15.11 | 39.35 | 33.01 | 30.83 |
| Gastroscopy | 21.06 | 20.02 | 30.90 | 29.02 |
| All 15 DM01 tests | 28.50 | 12.95 | 6.83 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In June 2026 (provisional), community services data recorded 78,050 contacts for Crawley residents, with 56,740 contacts among adults aged 65 and over, representing 72.7% of activity. These borough-level resident figures indicate heavy elderly community care demand across the local system, though they do not represent PCN-specific delivery.
Practice variation and patient experience
Telephone access varies by 23.0 pp across practices while overall experience spans 6.4 pp
Overall QOF achievement was 94.5% at Leacroft Medical Practice, whereas Southgate Medical Group achieved 97.7% (England 92.5%). Across captured practices, the range in QOF vaccination and immunisation-domain achievement is 17.0 pp. Bridge Medical Centre achieved 62.3%, whereas Southgate Medical Group achieved 79.3% (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Leacroft Medical | 94 | 0.0 | 76.4% | 76.8% | 84.2% |
| Southgate Medical | 100 | 1.1 | 56.1% | 64.0% | 79.5% |
| Langley Corner | 102 | 0.0 | 53.4% | 67.3% | 78.8% |
| Bridge | 95 | 0.0 | 68.1% | 63.2% | 77.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 measures trail England over three years, led by contracting registers
Over 2023 to 2025, 15 of 25 measures trail England's three-year change. Trailing registers lead the lag: dementia prevalence fell 19.5% (England +6.0%), stroke fell 2.4% (England +2.3%), and depression fell 1.2% (England +7.7%), while smoking cessation support dropped 3.8 pp (England +0.1 pp). Conversely, review delivery showed notable growth: COPD reviews rose 25.1% (England +2.8%), psychosis alcohol recording increased 11.7 pp (England +5.4 pp), and asthma reviews rose 9.5% (England +4.4%). This pattern is consistent with expanding review delivery alongside slower disease identification or recording.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Depression register
Cancer register
Hypertension register
Stroke register
COPD reviews
Alcohol record (psychosis)
Asthma reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Crawley | Asset | PCN | Crawley |
|---|---|---|---|---|---|
| Care homes (catchment) | 23 (395 beds) | n/a | Schools (catchment) | 84 | n/a |
| Children's centres | 7 | 7 | Places of worship | 51 | 45 |
| Libraries | 2 | 2 | Food banks (VCS) | 1 | no data |
| Homelessness support (VCS) | 0 | no data | Day centres (VCS) | 1 | 1 |
| Carers support groups (VCS) | 1 | 1 | Primary schools (LA maintained) | 12 | 10 |
| Primary academies | 13 | 14 | Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension case-finding and coding audit
Recorded prevalence is 13.3% (6,811 patients) vs 13.8% in Crawley and 15.2% in England (+0.6% 3-year change vs +5.6% in England), giving an unadjusted scenario of +348 to +1,065 patients. Low cost, quick to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Structured annual asthma review recall
Asthma review coverage is 67.4% (Crawley 68.7%, England 65.7%; 51.0% at Bridge Medical Centre), leaving a scale estimate of 1,067 patients without a recorded review across 3,272 patients. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Stroke and dementia register validation
Stroke prevalence is 1.4% (729 patients; Crawley 1.5%, England 1.9%), a +31 to +248 scenario; dementia is 0.5% (278 patients; Crawley 0.4%, England 0.8%), a -51 to +127 scenario. For discussion: practices could audit discharge coding and care-home records to test whether register contractions reflect list turnover or missed diagnoses. Moderate effort to run.
Evidence base: the stroke/TIA register is the cohort for AF anticoagulation and blood-pressure control (pre-stroke prevention) as well as hyperacute care; practices well below expected prevalence are the case-finding list, and the pre-stroke prevention gap concentrates in deprived practices.
Policy anchor: Core20PLUS5 (CVD); NHS CVD ambitions to 2029.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted communication and engagement (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Targeted Core20 clinical outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Targeted smoking cessation support (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension case finding and recall (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer coding and register review (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Telephone access workflow review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension case-finding and coding audit (p12) | Hypertension register · Hypertension: QOF prevalence · Aged 65+ | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Structured annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 3 · Stroke and dementia register validation (p12) | Stroke register · Stroke: QOF prevalence · Dementia register | Core20PLUS5 CVD · CVDPREVENT · SSNAP · 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
